Transaction in Own Shares • Nov 14, 2014
Transaction in Own Shares
Open in ViewerOpens in native device viewer
November 14, 2014
As of November 13, Novozymes has purchased an accumulated 7,032,696 shares with a transaction value of DKK 1,811.3 million under the stock buyback program Novozymes announced in Company announcement No. 17, 2014 and initiated February 17, 2014. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2014.
The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:
| Number of shares |
Average purchase price |
Transaction value, DKK |
|
|---|---|---|---|
| Accumulated, last announcement | 6,882,696 | 1,769,950,361 | |
| November 7, 2014 | 30,000 | 274.27 | 8,228,057 |
| November 10, 2014 | 30,000 | 273.80 | 8,213,953 |
| November 11, 2014 | 30,000 | 277.04 | 8,311,177 |
| November 12, 2014 | 30,000 | 276.14 | 8,284,171 |
| November 13, 2014 | 30,000 | 275.50 | 8,264,966 |
| Total accumulated under the program | 7,032,696 | 1,811,252,685 |
In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 5,106 B shares in the period from November 7 to November 13, 2014. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.
Following the transactions stated above, Novozymes owns a total of 10,892,954 treasury shares, corresponding to 3.4% of the stock capital. The total number of shares in the company is 319,700,000, including treasury shares.
| Investor Relations: | ||
|---|---|---|
| Thomas Bomhoff (DK) | +45 3077 1226 | [email protected] |
| Klaus Sindahl (DK) | +45 5363 0134 | [email protected] |
| Martin Riise (USA) | +1 919 649 2565 | [email protected] |
| Press and media: | ||
| Rene Tronborg (DK) | +45 3077 2274 | [email protected] |
| Frederik Bjoerndal (Europe) | +44 7976138265 | [email protected] |
| Paige Donnelly (USA) | +1 919 218 4501 | [email protected] |
| Meng Lian (China) | +86 136 9923 1164 | [email protected] |
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com
Company announcement No. 73, 2014 Page 1 of 1
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.